EU Clinical Trial Information System (CTIS)

Brand Logo

Brand Logo Light

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

I searched for some studies on AstraZeneca Clinical Trials, and found these studies that may also be of interest to you.
Here is the link to my search results

Official Title

Aclidinium bromide 200 μg once-daily by inhalation

To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.

A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD)

NCT ID

Therapeutic Area

Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks

Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks

Almirall Investigational Sites#947

Almirall Investigational Sites#644

Almirall Investigational Sites#645

Almirall Investigational Sites#646

Almirall Investigational Sites#647

Almirall Investigational Sites#649

Almirall Investigational Sites#110

Almirall Investigational Sites#393

Almirall Investigational Sites#394

Almirall Investigational Sites#651

Almirall Investigational Sites#652

Almirall Investigational Sites#653

Almirall Investigational Sites#654

Almirall Investigational Sites#655

Almirall Investigational Sites#656

Almirall Investigational Sites#657

Almirall Investigational Sites#658

Almirall Investigational Sites#953

Almirall Investigational Sites#971

Almirall Investigational Sites#972

Almirall Investigational Sites#659

Almirall Investigational Sites#660

Almirall Investigational Sites#661

Almirall Investigational Sites#662

Almirall Investigational Sites#664

Almirall Investigational Sites#665

Almirall Investigational Sites#666

Almirall Investigational Sites#954

Almirall Investigational Sites#390

Almirall Investigational Sites#397

Almirall Investigational Sites#398

Almirall Investigational Sites#549

Almirall Investigational Sites#593

Almirall Investigational Sites#594

Almirall Investigational Sites#669

Almirall Investigational Sites#671

Almirall Investigational Sites#672

Almirall Investigational Sites#750

Almirall Investigational Sites#752

Almirall Investigational Sites#948

Almirall Investigational Sites#191

Almirall Investigational Sites#675

Almirall Investigational Sites#677

Almirall Investigational Sites#678

Almirall Investigational Sites#680

Almirall Investigational Sites#681

Almirall Investigational Sites#757

Almirall Investigational Sites#758

Almirall Investigational Sites#765

Almirall Investigational Sites#766

Almirall Investigational Sites#682

Almirall Investigational Sites#683

Almirall Investigational Sites#684

Almirall Investigational Sites#685

Almirall Investigational Sites#686

Almirall Investigational Sites#687

Almirall Investigational Sites#688

Almirall Investigational Sites#689

Almirall Investigational Sites#286

Almirall Investigational Sites#459

Almirall Investigational Sites#635

Almirall Investigational Sites#694

Almirall Investigational Sites#777

Almirall Investigational Sites#346

Almirall Investigational Sites#348

Almirall Investigational Sites#551

Almirall Investigational Sites#695

Almirall Investigational Sites#696

Almirall Investigational Sites#697

Almirall Investigational Sites#698

Almirall Investigational Sites#699

Almirall Investigational Sites#700

Almirall Investigational Sites#701

Almirall Investigational Sites#702

Almirall Investigational Sites#705

Almirall Investigational Sites#706

Almirall Investigational Sites#709

Almirall Investigational Sites#711

Almirall Investigational Sites#712

Almirall Investigational Sites#713

Almirall Investigational Sites#714

Almirall Investigational Sites#715

Almirall Investigational Sites#961

Almirall Investigational Sites#962

Almirall Investigational Sites#970

Almirall Investigational Sites#462

Almirall Investigational Sites#465

Almirall Investigational Sites#540

Almirall Investigational Sites#543

Almirall Investigational Sites#582

Almirall Investigational Sites#588

Almirall Investigational Sites#716

Almirall Investigational Sites#717

Almirall Investigational Sites#718

Almirall Investigational Sites#719

Almirall Investigational Sites#720

Almirall Investigational Sites#721

Almirall Investigational Sites#722

Almirall Investigational Sites#785

Almirall Investigational Sites#786

Clinical trial assessing efficacy and safety of LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD) patients

Trough FEV1 (mean of two highest FEV1 values assessed at 23 and 24 hours after inhalation) at 28 weeks

Trough FEV1 (mean of two highest FEV1 values assessed at 23 and 24 hours after inhalation) at 12 weeks

Age Categorical

Age Continuous

Gender, Male/Female

Region of Enrollment

Intention-to-Treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and had at least the baseline and one post-baseline value available for the primary efficacy variable.

Trough FEV1 (L) at 28 Weeks on Treatment

Time to first moderate or severe exacerbation:
Increase of COPD symptoms during at least 2 consecutive days, treated with antibiotics and/or systemic corticosteroids or an increase in dose of systemic corticosteroids, or leading to hospitalisation.

Time to First Moderate or Severe COPD Exacerbation at 52 Weeks on Treatment

Yes (% Patients with 4-unit decrease)

No (% Patients without 4-unit decrease)

Percentage of patients who achieved a clinically relevant improvement in health-related quality of life at 52 weeks, as measured by at least a 4-unit decrease from baseline in St George's Respiratory Questionnaire (SGRQ) total score

Percentage of Patients Who Achieved at Least a 4-unit Decrease From Baseline in the SGRQ Total Score at 52 Weeks on Treatment

Trough Forced Expiratory Volume in the first second (FEV1) (L) at 12 Weeks on Treatment

Overall Study

Following a screening visit, patients entered a 14-day run-in period during which they used inhaled
salbutamol administered via a pressurised metered dose inhaler (pMDI) as rescue medication on an “as
needed” basis. The 14-day run-in period was used to assess the stability of each patient’s disease and baseline characteristics.

AstraZeneca Clinical

Arms	Assigned Interventions
Experimental: Aclidinium 200 μg once-daily Aclidinium bromide 200 μg once-daily by inhalation	Drug: Aclidinium bromide Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
Placebo Comparator: Placebo Placebo once-daily via inhalation	Drug: Placebo Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks

A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD)

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

Sponsor web site

Co-Sponsor web site

CSR Synopsis

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator